Dir
Paula Soteropoulos is a seasoned biotech executive with over 30 years of experience in strategic and operational leadership across pharmaceuticals and biotechnology, including rare diseases, cardiovascular, metabolism, infectious diseases, renal, transplant, and oncology.[[1]](https://www.htgc.com/39-authentic-leadership-advancing-biotech-and-womens-health-featuring-paula-soteropoulos/)[[2]](https://www.bio.org/events/bio-international-convention/speakers/1994773) She serves as a Venture Partner at 5AM Ventures, Chairman of the Board of Ensoma (where she was founding Executive Chairman), and as a Director on the boards of Dianthus Therapeutics (DNTH), Rallybio, uniQure, and Kyowa Kirin.[[1]](https://www.htgc.com/39-authentic-leadership-advancing-biotech-and-womens-health-featuring-paula-soteropoulos/)[[2]](https://www.bio.org/events/bio-international-convention/speakers/1994773)[[3]](https://www.stocktitan.net/sec-filings/DNTH/form-4-dianthus-therapeutics-inc-de-insider-trading-activity-3a7a1778b844.html) On March 31, 2026, as a DNTH director, she exercised options for 599 shares at $8.44 and sold them at $80.11.[[3]](https://www.stocktitan.net/sec-filings/DNTH/form-4-dianthus-therapeutics-inc-de-insider-trading-activity-3a7a1778b844.html)[[4]](https://www.sahmcapital.com/news/content/dianthus-therapeutics-director-paula-soteropoulos-disposes-of-shares-worth-0-million-2026-04-02)[[5]](https://www.investing.com/news/insider-trading-news/dianthus-therapeutics-director-soteropoulos-sells-47985-in-stock-93CH-4594358)
Soteropoulos was the founding CEO and Director of Akcea Therapeutics, where she led the company public via IPO, built operations in 13 countries, and launched two rare disease drugs.[[1]](https://www.htgc.com/39-authentic-leadership-advancing-biotech-and-womens-health-featuring-paula-soteropoulos/)[[2]](https://www.bio.org/events/bio-international-convention/speakers/1994773) Previously, she held roles as SVP and General Manager of Cardiometabolic and Rare Disease Businesses at Moderna, and over 20 years at Genzyme, culminating as VP and General Manager of Cardiovascular and Rare Diseases.[[2]](https://www.bio.org/events/bio-international-convention/speakers/1994773) She advises Chiesi USA, Kyowa Kirin North America, and Tufts University’s Chemical and Biological Engineering Department, and mentors women leaders through Women in Bio and the Termeer Foundation.[[1]](https://www.htgc.com/39-authentic-leadership-advancing-biotech-and-womens-health-featuring-paula-soteropoulos/)[[2]](https://www.bio.org/events/bio-international-convention/speakers/1994773)
View full insider profile →
Discussion